AstraZeneca PLC

AZN · LSE · Healthcare · £192B

Technical Bias: Bearish lean

12,566p+202.00p (+1.63%)Delayed

As of Jul 15, 2026 · Source: EODHD

Price history

Daily candles · adjusted close

As of Jul 15, 2026 · Source: EODHD

Performance

+1.63%

-11.76%

-5.40%

-14.90%

YTD

-7.93%

+22.51%

As of Jul 15, 2026 · Source: Computed · EODHD OHLC

Technical indicators

RSI (14): 35.8Neutral
MACD (12,26,9): -197.97Bearish
Moving averages: 50: 13640 · 200: 13741.4Bearish
Support / Resistance: 13,838p / 14,686p

Technical Bias

Bearish lean

0 Bullish · 2 Bearish · 1 Neutral

A transparent read of the indicators below — not a prediction or recommendation.

As of Jul 15, 2026 · Source: Computed · EODHD OHLC

Fundamentals

Market cap: £192B
P/E ratio: 24.58
EPS: 5.03p
Profit margin: 17.19%
Revenue growth (YoY): +12.5%
Free cash flow: £8.67B
Beta: 0.23
52-week range: 9,892p – 15,730p
Dividend yield: 1.87%
Ex-dividend date: Feb 19, 2026
Next earnings: —

As of Jul 15, 2026 · Source: EODHD

Latest news

AstraZeneca (LSE:AZN) Secures Zegfrovy In $1.5 Billion Lung Cancer Licensing DealPositive
Jul 15, 2026
HSBC downgrades AstraZeneca after key trial failureNegative
Jul 13, 2026
UBS stays positive on AstraZeneca ahead of second-quarter resultsPositive
Jul 13, 2026
AstraZeneca stock dips as HSBC downgrades stock on ’tough path ahead’Positive
Jul 13, 2026
Panic grips Ionis Pharmaceuticals investors amid bad news spreeNegative
Jul 12, 2026
Is Alnylam Pharmaceuticals (ALNY) Cheap As Rival Trial Failure Shifts ATTR CM Expectations?Positive
Jul 11, 2026

As of Jul 15, 2026 · Source: EODHD

AI-assisted research for informational purposes only — not investment advice. Figures are sourced from third-party market data and may be delayed. Do your own research before trading. Your capital is at risk.